Biotechnology
Lundbeck presents new Vyepti® (eptinezumab) and bocunebart migraine portfolio data at EAN 2026
* Five migraine presentations will showcase Lundbeck's current and future approaches to migraine prevention, including new data for eptinezumab and Phase IIb PROCEED primary data for the investigational treatment, bocunebart * Eptinezumab data explore patient-centered outcomes in chronic migra...
2026-06-24 16:08
3455
WuXi Biologics' 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations
SHANGHAI, June 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG17 drug substance facility located at the Shanghai Fengxian site has successfully completed its first GMP production camp...
2026-06-24 14:39
5116
UniXell Biotechnology Secures FDA IND Clearance for UX-DA003, Achieving China-U.S. Dual Breakthrough in iPSC Parkinson's Therapy
SHANGHAI, June 23, 2026 /PRNewswire/ -- UniXell Biotechnology Co., Ltd. ("UniXell") has secured Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for UX-DA003, its allogeneic induced pluripotent stem cell (iPSC)-derived therapy for Parkinson's disease. Pair...
2026-06-24 14:04
3414
Cynosure Lutronic Spotlighted Structural Skin Tightening Innovation at IMCAS Asia 2026 in Bangkok
SINGAPORE, June 24, 2026 /PRNewswire/ -- Global medical aesthetics leader Cynosure Lutronic presented its latest non-invasive innovations at IMCAS Asia 2026 in Bangkok (19–21 June), featuring XERF™, a structural skin tightening treatment that focuses on comfort, safety, flexibility and no downtim...
2026-06-24 13:14
4725
Abbisko Therapeutics Deepens R&D Collaboration with Lilly
SHANGHAI, June 23, 2026 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic research collaboration and license agreement with Eli Lilly and Company ("Lilly"), a leading global pharmaceutical co...
2026-06-24 09:00
3778
Mabwell Receives IND Clearance from NMPA for LILRB4/CD3-targeting TCE Bispecific Antibody 6MW5311
SHANGHAI, June 23, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the National Medical Products Administration (NMPA) of China has cleared the clinical trial application for its innovative L...
2026-06-24 08:00
4251
Abu Dhabi Opens Strategic Life Sciences Corridor to California Through Biocom Partnership
ABU DHABI, UAE, June 24, 2026 /PRNewswire/ -- The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, and Biocom California, one of the world's largest life sciences associations representing more than 1,800 biotechnology, pharmaceutical and medical techno...
2026-06-24 07:11
4179
Haisco Enters into Exclusive License Agreement with Nuvectis for Two Drug Candidates in Oncology and Complement Indications
BEIJING, June 23, 2026 /PRNewswire/ -- On June 23, 2026 (Beijing time), Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement withNuvectis, a U.S. biotechnology company. Under the agreement, Haisco has granted Nuvectis the ...
2026-06-23 21:17
3915
CPHI/ Hi Korea 2026 Opens Pre-Registration: Korea's Hub for Pharma, Biopharma, and Health Innovation
SEOUL, South Korea, June 23, 2026 /PRNewswire/ -- Informa Markets Korea has
officially opened pre-registration for CPHI/ Hi Korea 2026, taking place at
COEX, Seoul, from August 25 to 27. Pre-registered visitors enjoy complimentary
entries.
2026-06-23 08:00
5742
Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions
MELBOURNE, Australia and INDIANAPOLIS, June 23, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces an educational webinar exploring the unmet needs in neurologic oncology (specifically glioma and glioblastoma) and how theranostics may help address ...
2026-06-23 05:37
6592
Texas A&M Study Highlights Pictor PictVet® as a Promising New Tool for Non-Invasive Beef Cattle Health Monitoring
Independent peer-reviewed research published in Frontiers in Veterinary Science reports strong assay performance in a proof-of-concept evaluation using bovine nasopharyngeal swab samples CARLSBAD, Calif., June 23, 2026 /PRNewswire/ -- Pictor Holdings Inc., a global targeted proteomic platform co...
2026-06-23 01:37
3592
CJ BIO to Showcase TasteNrich® Taste Lab for Sodium Reduction, Clean Label, and Taste Design Solutions at IFT FIRST 2026
"Not Just Reducing, But Designing Better Taste" CHICAGO and DOWNERS GROVE, Ill., June 22, 2026 /PRNewswire/ -- CJ BIO will participate in IFT FIRST 2026, taking place July 13–15, 2026, at McCormick Place in Chicago. At Booth #1117, CJ BIO will introduce the TasteNrich® Taste Lab, an application-...
2026-06-22 23:39
4775
CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors
SHANGHAI, June 22, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that as informed by the National Medical Products Administration ("NMPA") today, the New Drug Application ("NDA") of sat...
2026-06-22 19:33
5250
CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors
SHANGHAI, June 22, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that as informed by the National Medical Products Administration ("NMPA") today, the New Drug Application ("NDA") of sat...
2026-06-22 19:20
4140
ChemT Biotechnology Raises US$5 Million in 18 months to bring AI to Biomanufacturing
* The total funding comprises US$1 million in angel investment and a US$4 million seed round. The seed financing round was led by Wavemaker Ventures, with participation by SEEDS, further supported by notable investors across the United States and Asia. * The financing will support the continu...
2026-06-22 17:15
3757
Piramal Pharma Solutions Highlights Strong Performance Across More Than 200 Customer Audits
* Piramal Pharma Solutions completed more than 200 customer audits and received over 70 approvals from regulatory agencies across its global network over the past year, with strong overall outcomes. * This milestone reflects the Company's long-range quality strategy focused on sustained compl...
2026-06-22 16:57
3432
Innogen Pharmaceutical Group Highlights China-Originated Innovation and Global Development Strategy at DIA Global Annual Meeting 2026 China Town Hall
From original GLP-1 science to international clinical development, Innogen shares its "from 0 to 1" innovation journey in metabolic diseases PHILADELPHIA, June 22, 2026 /PRNewswire/ -- During the DIA Global Annual Meeting 2026 held in Philadelphia, the China Town Hall session was successfully co...
2026-06-22 16:39
3123
Translational Research Results of Sacituzumab Tirumotecan (sac-TMT) in Combination with Osimertinib as First-Line Treatment for EGFR-Mutant NSCLC Published in Cancer Cell
— The study shows that EGFR-TKIs induce TROP2 upregulation in DTP cells, providing a mechanistic basis for combining sac-TMT with EGFR-TKI. — The Company is conducting a Phase III registrational study of sac-TMT plus osimertinib as first-line treatment for advanced EGFR-mutant NSCLC (enrollment ...
2026-06-22 14:00
5401
Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders
CAMBRIDGE, Mass., June 22, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and SK Biopharmaceuticals, a Korean-based company leads the way in biotech innovation with groundbreaking drug research,...
2026-06-22 12:37
5044
Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE
* ATG-106 is a first-in-class CDH6 x CD3 bispecific T cell engager (TCE) in preclinical development for the treatment of solid tumors * K2 Therapeutics, established by MPM BioImpact, obtains exclusive global rights to develop and commercialize ATG-106 outside Greater China * Antengene r...
2026-06-22 08:30
4532
Week's Top Stories
Most Reposted
Mastercard elevates premium travel with Asia Pacific's first Taste by Priceless dining club at Hong Kong International Airport
[Picked up by 325 media titles]
2026-08-05 11:34
MetaOptics Sharpens Focus on Metalens Commercialisation; Withdraws Nasdaq Listing Application, and Defers U.S. Dual Listing Plan
[Picked up by 305 media titles]
2026-08-07 22:30Hyatt Regency Kuala Lumpur At KL Midtown: A Refined Urban Retreat Recognised For Design Excellence
[Picked up by 296 media titles]
2026-08-04 07:00
Thailand Ready to Welcome 191 Countries to the 2026 Annual Meetings of the International Monetary Fund and the World Bank Group
[Picked up by 296 media titles]
2026-08-06 15:10
Vitafoods Asia Announces Strategic Move to Kuala Lumpur for 2027 Edition
[Picked up by 292 media titles]
2026-08-04 14:30
Most Read
Hyatt Regency Kuala Lumpur At KL Midtown: A Refined Urban Retreat Recognised For Design Excellence
2026-08-04 07:00
9299
Mastercard elevates premium travel with Asia Pacific's first Taste by Priceless dining club at Hong Kong International Airport
2026-08-05 11:34
6834
Singapore Good Soil Foundation Hosts Third Next Generation Philanthropy Leadership Program at the University of Hong Kong, Empowering the Next Generation of Global Changemakers
2026-08-02 02:09
6430
Gene Solutions Advances Precision Oncology Education in Malaysia with the ''Beyond Actionable'' Academy
2026-08-04 06:00
5793
Vitafoods Asia Announces Strategic Move to Kuala Lumpur for 2027 Edition
2026-08-04 14:30
5500